Biomarker Types Overview

Overview

Biomarker Types Overview is a topic within the NeuroWiki knowledge base covering aspects of neurodegenerative disease research and mechanisms. [@csf2011]

Biomarkers are measurable indicators of biological processes, disease states, or therapeutic responses. In neurodegenerative diseases, biomarkers provide objective measures of pathology, enable early detection, track disease progression, and evaluate treatment effects. This overview covers the major biomarker categories used in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions. [@csf2011a]

Biomarker Categories

1. Fluid Biomarkers

Fluid biomarkers are measured in cerebrospinal fluid (CSF), blood (plasma/serum), or other bodily fluids. [@csf2014]

Cerebrospinal Fluid (CSF) Biomarkers

CSF directly reflects brain biochemistry through the [blood-brain barrier](/entities/blood-brain-barrier) [1](https://pubmed.ncbi.nlm.nih.gov/21251454/). [@nfl2017]

Alzheimer's Disease Biomarkers: [@blood2021]

• [Amyloid-beta](/proteins/amyloid-beta) 42: Decreased in AD due to plaque deposition; 50-70% reduction compared to controls [2](https://doi.org/10.1016/j.jalz.2011.09.224)
• Amyloid-beta 40: Reference peptide; Aβ42/40 ratio improves accuracy
• Total [tau](/proteins/tau) (t-tau): Elevated in AD; reflects neuronal damage
• Phosphorylated tau (p-tau): AD-specific; correlates with neurofibrillary tangles [3](https://doi.org/10.1001/jamaneurol.2014.2359)

Overview

Biomarker Types Overview is a topic within the NeuroWiki knowledge base covering aspects of neurodegenerative disease research and mechanisms. [@csf2011]

Biomarkers are measurable indicators of biological processes, disease states, or therapeutic responses. In neurodegenerative diseases, biomarkers provide objective measures of pathology, enable early detection, track disease progression, and evaluate treatment effects. This overview covers the major biomarker categories used in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions. [@csf2011a]

Biomarker Categories

1. Fluid Biomarkers

Fluid biomarkers are measured in cerebrospinal fluid (CSF), blood (plasma/serum), or other bodily fluids. [@csf2014]

Cerebrospinal Fluid (CSF) Biomarkers

CSF directly reflects brain biochemistry through the [blood-brain barrier](/entities/blood-brain-barrier) [1](https://pubmed.ncbi.nlm.nih.gov/21251454/). [@nfl2017]

Alzheimer's Disease Biomarkers: [@blood2021]

• [Amyloid-beta](/proteins/amyloid-beta) 42: Decreased in AD due to plaque deposition; 50-70% reduction compared to controls [2](https://doi.org/10.1016/j.jalz.2011.09.224)
• Amyloid-beta 40: Reference peptide; Aβ42/40 ratio improves accuracy
• Total [tau](/proteins/tau) (t-tau): Elevated in AD; reflects neuronal damage
• Phosphorylated tau (p-tau): AD-specific; correlates with neurofibrillary tangles [3](https://doi.org/10.1001/jamaneurol.2014.2359)

• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Marker of axonal degeneration; elevated in PD and atypical parkinsonism [4](https://pubmed.ncbi.nlm.nih.gov/29051483/)
• [Alpha-synuclein](/proteins/alpha-synuclein): Total and phosphorylated forms; seeding assays detect pathology

• Neurofilament light chain (NfL): Prognostic marker; higher levels = faster progression
• Phosphorylated neurofilament heavy chain (pNfH): Disease severity marker

Blood-Based Biomarkers

Blood tests are less invasive and suitable for screening. [@hippocampal2002]

Key Blood Biomarkers: [@amyloid2013]

• p-tau181: Highly accurate for AD; correlates with amyloid and tau PET [5](https://doi.org/10.1038/s41591-021-01505-4)
• [p-tau217](/biomarkers/p-tau-217): May be even more specific than p-tau181; detects early AD [6](https://doi.org/10.1016/j.jneuralsci.2020.116926)
• NfL: Cross-disease marker of neurodegeneration; validated in many studies [7](https://doi.org/10.1038/s41582-019-0269-y)
• [GFAP](/entities/gfap): Astrocyte marker; elevated in AD

2. Neuroimaging Biomarkers

Neuroimaging provides structural and molecular information. [@tau2017]

Structural Imaging

MRI Biomarkers: [@apoe2010]

• Hippocampal atrophy: Key AD marker; measured by hippocampal volume [8](https://pubmed.ncbi.nlm.nih.gov/11806130/)
• Ventricular enlargement: Marker of brain volume loss
• White matter hyperintensities: Vascular contributions
• Regional atrophy patterns: Differentiates AD, FTD, DLB

Molecular Imaging

Amyloid PET: [@digital2020]

• Tracers: Florbetapir, flutemetamol, florbetaben
• Detects amyloid plaques in vivo
• Sensitivity >95%, specificity >90% [9](https://doi.org/10.1016/j.jalz.2013.01.013)

• Primary tracer: Flortaucipir (Avid)
• Visualizes neurofibrillary tangles
• Correlates with clinical severity [10](https://doi.org/10.1016/j.neurobiolaging.2017.02.012)

• DaT-SPECT: Confirms dopaminergic deficit in PD
• PET tracers: F-DOPA, CFT

3. Genetic Biomarkers

Genetic markers identify risk and confirm diagnosis.

Risk Factors:

• [APOE](/proteins/apoe) ε4: Strongest AD risk allele; 3-4x increased risk [11](https://pubmed.ncbi.nlm.nih.gov/19968377/)
• [LRRK2](/entities/lrrk2) G2019S: Most common PD mutation
• [GBA](/entities/gba): Carriers have increased PD risk and earlier onset
• [C9orf72](/entities/c9orf72): Most common ALS/FTD mutation

• [APP](/entities/app-protein), [PSEN1](/entities/psen1), [PSEN2](/entities/psen2): Autosomal dominant AD
• SNCA, LRRK2, GBA, PARK2: Monogenic PD
• SOD1, FUS, C9orf72: Familial ALS

4. Digital Biomarkers

Emerging technologies enable continuous monitoring.

Motion Sensors:

• Accelerometers detect tremor, bradykinesia
• Gait analysis identifies subtle changes
• Activity monitoring tracks overall function [12](https://doi.org/10.1001/jamaneurol.2020.2836)

• Reduced vocal complexity in PD
• Speech rate changes in AD
• Machine learning improves detection

• REM sleep behavior disorder (RBD) - prodromal PD/PD
• Sleep fragmentation common in neurodegeneration

5. Clinical Biomarkers

Standardized clinical measures serve as biomarkers.

Cognitive Assessments:

• MMSE, MoCA: Global cognition
• CDR: Dementia staging
• Executive function tests: Frontotemporal involvement

• UPDRS: PD severity
• ALSFRS-R: ALS functional rating
• Timed up and go: Mobility

Biomarker Panels by Disease

Alzheimer's Disease

| Biomarker | Type | Clinical Use |
|-----------|------|--------------|
| Amyloid PET | Imaging | Diagnosis |
| CSF Aβ42 | Fluid | Diagnosis |
| CSF p-tau | Fluid | Diagnosis, monitoring |
| Blood p-tau | Fluid | Screening |
| MRI atrophy | Imaging | Staging |

Parkinson's Disease

| Biomarker | Type | Clinical Use |
|-----------|------|--------------|
| DaT-SPECT | Imaging | Diagnosis |
| NfL | Fluid | Prognosis |
| Alpha-syn RT-QuIC | Fluid | Diagnosis |
| Genetic testing | Genetic | Risk, diagnosis |

ALS

| Biomarker | Type | Clinical Use |
|-----------|------|--------------|
| EMG | Clinical | Diagnosis |
| NfL | Fluid | Prognosis |
| pNfH | Fluid | Monitoring |
| Genetic testing | Genetic | Diagnosis, family planning |

Biomarker Validation Framework

AT(N) Classification

The AT(N) system standardizes biomarker reporting [13](https://doi.org/10.1016/j.jalz.2018.02.013):

• A: Amyloid biomarkers (Aβ PET, CSF Aβ42)
• T: Tau biomarkers (tau PET, CSF p-tau)
• (N): Neurodegeneration (MRI atrophy, FDG-PET, CSF t-tau)

Biomarker Staging

Biomarkers can detect disease stages:

Future Directions

Emerging Technologies

• Proteomics: Unbiased discovery of new markers
• [Exosomes](/entities/exosomes): Brain-derived vesicles for specific signals
• Multimodal AI: Combine biomarkers for precision

Clinical Translation

• Blood biomarkers for population screening
• Point-of-care testing
• Digital biomarker integration

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram